This is what intrigues me, if PPO's can't streamline sales, it just happened to happen straight after the agreement was made when they achieved their first commericial sales in the states...
Printable View
sorry I had a typo earlier. I meant that they can streamline sales and that's all they do.
Most commonly biotech startup companies have zero sales for up to five years or more during a research & development / early commercialisation phase.
Those who may attempt to apply p/s ratio’s during this phase clearly have little understanding as to how to value a company like PEB at this stage in its life.
Though I wish them well, they may be missing out on what’s a robust investment in PEB.
http://www.deloitte.com/view/en_CA/c...42f00aRCRD.htm
To mac, do you think the first sales were set off by the provider agreement?
http://www.youtube.com/watch?v=
Interesting DD mentions pacific edge already have their first customer who has ran approx 80 tests back in 31st jan 2013.
Must be Dr. Joe DiTrollo
I don't see why they should not have been Baller, the announcement of first commercial sales was very shortly after the FedMED sign up.
It's important to note also that although PEB haven’t been formally announced as such as a Medicare provider, the PEB website does offer this recent and rather interesting statement;
"Pacific Edge is a Medicare provider. Pacific Edge will accept patients with Medicare coverage, and these patients will have no financial responsibility for Cxbladder."
http://www.cxbladder.com/for-patients/billing-policy/
regards, Mac
Wouldn’t get to excited, by recent I mean over the last six months or so.
From the website it would seem that PEB are though presently accepting patients with Medicare coverage, but we also know that negotiations are ongoing between Pacific Edge and Medicare. This from the ODT, 28th December 2013.
“However, the next crucial step is Pacific Edge gaining clearance from the Centre for Medicaid and Medicare Services (CMS), which oversees and reimburses payments for the US public health system.
Swann welcomed Obama-care, but the legislative changes mean Pacific Edge has to wait longer and make changes to gain CMS accreditation, though he is hopeful it will be through early next year.”
http://www.nzherald.co.nz/business/n...ectid=11178639
If anyone is able to interpret those words ‘clearance’ and ‘accreditation’ then we may all be more enlightened.
It provides a nice paradox, how can billing occur without negotiations being final, perhaps there is some form of interim or transitory agreement in place ?
So if peb did not get coverage it would mean free tests? Logic is a bit flaw there
Coming back to Chris Swanns advice.
As we know the whole sector including CMS had a big shake up last year and it does take bureaucrats a good lengthy period to interpret and prepare policy following new mandates like the Obama-care legislation.
“Swann welcomed Obama-care, but the legislative changes mean Pacific Edge has to wait longer and make changes to gain CMS accreditation, though he is hopeful it will be through early next year.”
http://www.nzherald.co.nz/business/n...ectid=11178639
Fortunately for Pacific Edge most of that disruption seems to come and gone in early to mid 2013, and although PEB are probably still hurdle jumping even now we should be encouraged that accreditation is apparently close.
Once accredited it seems that the Obama-care legislation should greatly benefit companies like PEB. This assessment by Forbes provides some insight;
http://www.forbes.com/sites/genemarc...medical-tests/
It’s a five year plan, patiently onward and forward.
It's more probable, due to the timing of the cxbladder launch, that PEB are working through a specific process within CMS. Thus, while discussions and final accreditation is ongoing, PEB remain a medicare provider with a final commercial agreement governed by the legislative changes pending.
With PEB having been a Medicare provider for six months now, it does seem to put that anticipated 'tens of thousands of tests in 2014' advice from Chris Swann into some perspective.
http://www.cxbladder.com/for-healthc...illing-policy/
Are we going to see a big leap in price with announcements such as medicare approval etc? Do you think most of this was already priced in? Or do you feel that this will be a significant derisking event that will cause investors to flood in, in anticipation of the 10% market share becoming just the beginning?
Just throwing this out there, whats it going to take for PEB to be a $1billion dollar company?
That's all good.
But 1 stumble... and were back to 70c... jumping jack flash.
Not down ramping ( I hold ) .. but a lot of expectation here.
I even have a mate of a mate... he s a taxi driver and has been buying that's scary... fortunately I know no shoe shine boys.
Might be all factored into the price already as everyone already knows it's going to happen... They do say that the market is forward looking. Remember when we all thought that the price would boost when their US lab gained accreditation and then the SP ended up dropping a significant amount, as it was buy the rumour sell the fact?
Imho it is the sales that are the unknown factor. A result expecting " several tens of thousands" of tests is duly noted but what does it actually mean. It implies more than 20000 and thats all. But how much more is the big unknown and that is unlikely to be reflected in the SP.
As an aside to all this - I have read this thread fairly thoroughly and have never seen any reference to Canada.
Is this already combined into the USA operation or is that a separate market? It would seem that the cities of Vancouver, Calgary, Winnipeg, Toronto and Montreal would produce a fair quantity of patients requiring help.
What i was inferring was that Canada per se is part of the larger geographical area of North America.
I doubt that the 49th parallel is a demarcation line for rate of incidence of haematuria and no doubt that, as Cxbladder's potential filters through from the US, the Canadians will take some sort of position on it.
Heads up on CDY on asx. Price sensitive announcement
Bids were at .04 so far - since withdrawn
we are in trading halt, yes?
I sold out of snk blt brl and wyn this morning and added to my peb holding. Best decision ive made in my short time investing with shares :D
Has anyone an idea/guess on the amount of revenue income from NZ going forward?
Thank you Moosie.
Think I recall reading that the test would cost less in NZ than the $550 figure for USA?
I agree with whatsup. This shows that the DHBs have concluded that CxBladder offers enough benefits that it’s worthy of adoption. And that’s a good thing because hopefully it’s a sign of how it will be adopted overseas (particularly the US). It should also help in US conversations to be able to point to NZ as an example of a country that has adopted the technology on a large scale.
~$300 if my memory serves me right. This is a serious piece of additional news for the pipeline. Ignore Moosie's rubbish comment, there will be several thousand tests undertaken in NZ pa. I'm trying to find the info that scales up the number of tests generated by one incident of confirmed cancer, but my recollection is that it is many many many multiples
So about 5,000 present with symtoms each year in NZ.Quote:
About 50,000 cases of haematuria (blood in the urine) are anticipated in Australia and New Zealand, giving rise to about 3,000 new cases of bladder cancer in Australasia each year—80 percent of them among men.
http://www.idealog.co.nz/businessplan/first-defence
Someone just grabbed 700,000 so the back of the envelope figures must have appealed to them
RRP of US$250 in Aus/NZ, €200 in Europe, and US$768(3) in the U.S.
(composite CPT codes) versus US$600 - US$1000 for flexible cystoscopies
from the july 2011 cap raising doc
and this:
Following diagnosis, NCCN(2) guidelines say
patients will be monitored for 5 years and are
recommended to receive 12 cystoscopies
Brighton has it right here. PEB can now say "Over half of all people presenting with hematuria in New Zealand are now tested using our product because its so good." That is where the real upside will come from as NZ is often used as a test bed for all sorts of things due to our similarities with the US. A great point of leverage (providing they both start testing and it is successful) for future negotiations in the US/Europe.
Moosie, what you missed was the retest revenue available from this agreement and the number of presentations that 'generate' ~332 patients
Harveys number 5,000 tests per annum in NZ - sounds fair?half those at ~$300 = 750k
your number 332, times 5 years of existing patients, times say 2 tests per year for each patient, then halve it
so existing cases generate 332 * 2 *~300 *5 divided by 2 = ~500k
So on the basis of the figures people have published here, my best guess for revenues for the first year is $1.25m. I have missed another round of tests for those diagnosed from the 2,500 in the current year, but it's ~50k extra
I can't say the figures are reliable, but I would say there is a bit more logic in their calculation than the number that you rushed out in a hell of a hurry.
Anyway, what B_E says is actually more relevant to the impact of this announcement than crunching some numbers for their smallest market by far. Bring on the calcs for USA and Europe.....
Golly, said to myself that I won't check the share market today or go looking for news but BAM hear about PEB on the 6 o'clock news! Fantastic!!!
Only half of NZders the US may ask?
Yes this announcement is good news, way overdue I reckon. But I find it very perplexing that in a country such as NZ with a significant public health system, a Govt entity such as this can be set up to represent only 50% of the DHB's. I have personal baggage with the lack of communication and cooperation between DHB's at patient level and this just seems to confirm the "reinvent the wheel" attitude that seemingly pervades in this sector. uggh
Ten's of thousands of tests is definitely in reach now huh :)
I found the pdf document which has the detailed analysis of the US market but cannot upload it
Its called PEB investor Presentation 2011, page 27 has a table
The numbers produced earlier (remarkably) follow the logic of this presentation, EXCEPT for the number of retests generated in year two, (I used 2, when it seems to be 4)
The table has 1m tests generating 68,800 confirmed diagnoses, so 332 out of 5,000 is about the same proportion.
looked at from another angle, each confirmed case, typically generates 26 tests, which can act as a crosscheck of the logic, i.e. 165 * 26 * 300 is 1.3m pa
in the table, they generate US$100m at 10% penetration.....50%?......don't even go there........
Do you assume a mortality rate in your calcs
I exhaustively checked, crosschecked and triple checked the insurance mortality tables from 1922 to 2012 for a pattern, then compared it to the annual rates of increase for this particular cancer, relevant to the particular population under scrutiny, only to discover they exactly offset.....
Mr Magoo, thanks, I knew you'd deliver :t_up:
Doesn't all things that matter only exist in these 4 DHBs anyway so basically 100% of nz
Hancocks,
Atta boy!!
thats for 100% of the local market - a story for next.....month......
Nice announcement, but:
I think the word considered means that the sale of tests to the extent some people are anticipating is, at best, going to take time.Quote:
...As a result of the agreement Cxbladder will be considered for use to evaluate
patients presenting with haematuria...
Best Wishes
Paper Tiger
One can’t force a physician do anything, but procedures and guidelines will follow now, and there is no reason why the processes established during the user group programmes should not just roll over and become routine practice pretty much straight away.
It’s pleasing though Paper Tiger to see traders doing some analysis don’t you think.
So what are the procedures and guidelines?
Do a CxBladder test for everybody who has blood in the urine/suspected of BC?
Do a CxBladder test for that smaller group who meet these criteria?
Do not use as we do not have the funds to justify the cost/benefit analysis?
Best Wishes
Paper Tiger
Obviously a positive announcement today. I'm buoyed by the regulative nature of the announcement and consequences for promoting this on a bigger scale in other markets. If the test becomes protocol within governmental run establishments then we have a true "moat" quality to the product on two terms, IP and protocol/regimes. that's important in New Zealand. I still believe uptake of this test will be slower than any traders wish it to be. Large sales will be factored into the share price well before we see any such sales eventuate. This will cause wild share price fluctuations, all of which will have no effect on my current positive view of the company.
The work up costs are reduced for the DHB's by one third through the application of Cxbladder which should in itself help DHB management move on it.
One would expect the procedural outline to look similar if not the same to that below which I understand was developed by Pacific Edge closely in consultation with Urologists and the DHB's;
So yes it would seem likely that any poor unfortunate presenting with haematuria should receive at least one Cxbladder test, up to seven if they, heaven forbid, have cancer.
Attachment 5445
Thanks for the piccy MAC. Seem to have missed that
These articles provide more detail on the HIH arrangement.
http://www.stuff.co.nz/business/smal...der-DHB-access
http://www.odt.co.nz/news/business/2...z-breakthrough
Good news and may be there many more regular announcements to keep the shareprice pumping
Interesting the difference between all the financial analysis, from quick back of the envelope to more detailed ones. The range of eventual revenues from less than 1 mill to about 3 mill (without allowance for mortality) if I read them correctly.
Doesn't seem much in the context of the large aspirations. So not really a nz play and the world is where the money is to be made, hopefully. Nz just a springboard for future prosperity.
Still holding for the (inevitable) takeover by some big US player. That's my investment hypotheses.
But until that happens more announcements please to keep the price going up - more fun that way instead of holding dead money in hope of the takeover.
Good point. I wonder why they didn't think of that and build an even larger testing facility in a larger country like the US, and enter agreements with companies to do tests in the country with the highest bladder concentration like Spain? :)
I assume they will also target the Australian market, which is 10 times bigger, and the Ozzies will only be too happy to post their piss to the NZ testing facility???
I believe that Oryzon is the outfit licensed for Spain and Healthscope for Australia. Healthscope has its own laboratory approved by Pacific Edge in Australia. I think that they did the right thing by building a lab of sufficient size to handle the current forecast uptakes. A more rapid uptake will produce more revenue for additional labs if needed.
Still a lot of sellers at 1.74. Think we'll see 2 bux with medicare?
Umean sellers will disappear right before opening? More sellers ar 1.72 now
Gotcha u meant sellers will eventually disappear
Only 25 mins into the day...
First day after the announcement, who knows what will happen
Locked article on the NBR;
http://www.nbr.co.nz/article/why-pac...re-db-p-151703
Anyone got access who could summarise??
Thanks :)
Here you go:
Quote:
Ask David Darling to quantify financially what it means to have CxBladder adopted by the main district health boards (DHBs) and he remains guarded.
But the Pacific Edge [NZX: PEB] chief executive reckons having the backing of government agencyHealth Innovation Hub (HIH) for his company’s bladder cancer detection system is a tipping point for faster, better and sharper healthcare in New Zealand.
HIH has signed an agreement to fast track the introduction of Pacific Edge’s CxBladder technology to the four main DHBs, which cover half this country’s population.
The agreement is part of a move by the Ministry of Health to help push new technology into the mainstream, a process that is invariably bogged down by the clunky nature of the health system, Mr Darling says.
“This is recognition by the ministry that new technology just doesn’t get into these DHBs and the advantages and benefits to the New Zealand healthcare system are not being actioned because of this slow pathway in,” he says.
“We now have a dedicated agent on our product in each of those key jurisdictions and hopefully we will see a lot of these challenges that we’ve been running up against removed from our process.”
Pacific Edge's Cx-bladder uses a non-invasive urine sample for testing. It has certified labs in Pennsylvania and Dunedin that can respectively process up to 260,000 and 35,000 tests annually.
Being the guinea pig
The next step, Mr Darling says, may be to have the testing tool mandatorily accepted as the standard of care in New Zealand. That would give the company enormous marketing power in the US.
“That’s another happening and something we are working on,” Mr Darling says.
What he can say is that the product has already been evaluated by most DHBs and been validated through 200 patient user programmes.
“So it’s not about whether we want it, it’s about who pays and how we get it into the system.”
“We talk about wading through treacle and while it's nice and sweet, it’s damn hard work.
“The great thing for us now is there is a strong push coming from all around New Zealand and we are genuinely the guinea pig for this process because we are such a cute, clean technology with lots of upside.
“So they want to use this technology to change the processes to make the system faster sharper, better.”
Big savings
Mr Darling says CxBladder has the ability to deliver “significant savings in time and expense” for DHBs.
“If we are able to segregate one patient who doesn’t need a full workup, then the direct cost recovery to the DHB could be in excess of several thousand dollars.”
Then there are indirect costs such as the reallocation of resources – some patients are in queues for up to three months, he says.
The new Cxbladder diagnostic test costs around about $320, while a conventional full, invasive clinical test in New Zealand can cost between $1750 and $2200.
HIH was recently formed, with a mandate to enable technology commercialisation into and out of the country’s four largest DHBs.
HIH chief executive Frances Guyett says identifying and forming strategic relationships with key external partners to accelerate commercialisation by enabling access to DHBs is one of the HIH’s key objectives.
Like this part in particular
Being the guinea pig
The next step, Mr Darling says, may be to have the testing tool mandatorily accepted as the standard of care in New Zealand. That would give the company enormous marketing power in the US.
“That’s another happening and something we are working on,” Mr Darling says.
You're on the money Slam Dunk, this will be worth more to PEB than the few millions in revenues they will extract from the four or five million people inhabiting our humble islands.
The ability of Pacific Edge to hopefully demonstrate precedence internationally of the inclusion of Cxbladder into a national 'gold standard' is really the significant potential outcome of this relationship with the HIH.
It bodes well too for the ‘hot housing’ of the other pipeline products here also, hopefully Cxcolorectal becomes the next HIH agreement sometime this year.
Personally I like this one:
With quotes like that, and an increasing share price, they will get lots of news coverage, just like Drury does for XRO.Quote:
We talk about wading through treacle and while it's nice and sweet, it’s damn hard work.
What were you saying about announcements coming in 2's moosie? (apologies for big post below, announcement copied)
https://nzx.com/companies/PEB/announcements/246862
BOP & Lakes Urologists adopt Cxbladder
12:35pm, 11 Feb 2014 | GENERAL
11 February 2014
BOP and Lakes Urologists adopt Cxbladder
Patients presenting with symptoms of bladder cancer and those under surveillance of bladder cancer in the Bay of Plenty and Lakes District Health Board regions will now be evaluated as part of their clinical program, with Pacific Edge’s non-invasive urine sampling Cxbladderdetect test.
Bay of Plenty and Lakes District urologists are the latest to join the list of New Zealand clinicians and DHB’s who are being signed by Pacific edge Diagnostics to offer their patients Cxbladderdetect. Cxbladder is a superior technology with its ability to detect nearly 100 per cent of urinary tract carcinomas , in preference to cytology for the detection and monitoring of patients who may have bladder cancer.
Like MidCentral DHB, which began using Cxbladderdetect in June, BOP urologists will use Cxbladderdetect to evaluate patients presenting with blood in the urine (haematuria) as part of their clinical regime. This new strategy is expected to involve local GPs (the patient’s primary point of contact when symptoms occur) using Cxbladderdetect to help prioritise those patients who need to be seen urgently. They will also be able to identify low risk patients who do not require a full clinical work-up for bladder cancer, saving the public health system considerable associated expense, not to mention the inconvenience to the patients. Less than one in twenty of those patients with micro-haematuria are found to need further treatment for bladder cancer.
Pacific Edge is a Dunedin-based cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests. Pacific Edge Chief Executive Officer David Darling says there are significant potential savings to be made in the New Zealand health budget if all DHBs adopt Cxbladderdetect for the early evaluation and further analysis of patients presenting with haematuria.
“Many New Zealanders may have heard Sir Peter Leitch talk on television last year about the ease of use and high degree of confidence he and his clinician had in Cxbladderdetect (http://tvnz.co.nz/national-news/nz-c...-video-5234521) for monitoring his recovery from bladder cancer”. Those benefits are now being made available to nearly half a million New Zealanders [488,280 : pop numbers from MOH website] within the BOP, Lakes regions and the Mid Central DHB.
“Cxbladderdetect will allow clinicians in these three regions to provide better clinical outcomes for patients referred for urological evaluation and contribute considerable efficiencies for patients and healthcare providers, from its use.”
Bay of Plenty urologist, Mark Fraundorfer says that now is the right time to start using Cxbladderdetect. “Pacific Edge have gathered the clinical data and published in a peer reviewed journal, and the superior performance over cytolgy is clear. BOP (and Lakes) urologists have used Cxbladderdetect in a variety of clinivcal settings in both public and our private clinics over the last nine months, confirming the performance of the technology. Cxbladderdetect provides better information about the patients being referred to urologists and allows us to increase our focus on the patients that need further evaluation and treatment, and will avoid a significant number of unnecessary procedures. This is a good outcome for both the patients and the public health system as a whole.”
A recently completed clinical user programme involving 178 patients undertaken by Waitemata District Health Board and Urology Associates in conjunction with Canterbury DHB has confirmed the successful results of a multi-centre international peer reviewed study of 485 patients published in the prestigious American Journal of Urology in September 2012. Both studies showed that Cxbladderdetect identified correctly nearly 100 per cent of tumours of concern to clinicians, including those that cytology and several that cystoscopy did not identify. The results of the two centre New Zealand user programme are expected to be formally published later this year.
For clinicians and DHBs focused on providing the very best cost effective healthcare for New Zealanders, Cxbladderdetect provides a number of significant advantages that have the potential to change clinical practice and lower the overall cost of managing the patient’s disease:
• The Cxbladderdetect Urine Sampling System (USS) can be sent directly to the patient at home or to their GP clinic, thereby reducing waiting times to see a specialist within the public hospital system.
• Cxbladderdetect provides an accurate and cost effective way of evaluating patients presenting with blood in their urine (haematuria), before they get to the clinic and
• Cxbladderdetect is non-invasive and enhances a patient’s compliance with their cancer management regime as defined by the urologist.
For further information please contact
David Darling
Chief Executive Officer
Pacific Edge Limited
P: +64 (3) 4795800
After a quick skim this point seems prominent to me, "Like MidCentral DHB, which began using Cxbladderdetect in June, BOP urologists will use Cxbladderdetect to evaluate patients presenting with blood in the urine (haematuria) as part of their clinical regime. This new strategy is expected to involve local GPs (the patient’s primary point of contact when symptoms occur) using Cxbladderdetect to help prioritise those patients who need to be seen urgently."
I would have thought getting the tests in at the GP level would result in higher number of tests being utilized quicker as opposed to just when they have been referred to DHB clinics/hospitals etc
I read that as the DHB wont take a referral unless they have done the test, as it is used to prioritize patients. Therefore very positive as it means it will be pushed out fast.
What does concern me is if MidCentral has been using since June, why were there so few sales in the September update.
It's all about momentum, isn't it? As we have collectively determined, it's not a lot of revenue, when compared to the golden fleece, but we have momentum. The first pebble has hit the lake surface - waiting for the ripples now
Very excited by this. Particularly this part
"Like MidCentral DHB, which began using Cxbladderdetect in June, BOP urologists will use Cxbladderdetect to evaluate patients presenting with blood in the urine (haematuria) as part of their clinical regime. This new strategy is expected to involve local GPs (the patient’s primary point of contact when symptoms occur) using Cxbladderdetect to help prioritise those patients who need to be seen urgently. They will also be able to identify low risk patients who do not require a full clinical work-up for bladder cancer, saving the public health system considerable associated expense, not to mention the inconvenience to the patients."
I went to a PEB presentation at First NZC late last year where David talked about their intention to try to get CxBladder to be used by primary care doctors (GPs), which naturally means a lot more tests. It would appear they're having some success achieving this. Awesome!!
I actually think this latest announcement is bigger than the previous one because of their success in getting in at the GP level.
Pacific Edge has been pursuing a commercialisation programme since 2011, this programme required the completion of clinical trials, regulatory approvals, user group programmes, the commissioning of two laboratories, and a target of achieving first US sales in 2013.
Most investors I believe would agree that Pacific Edge have performed very well in meeting all these objectives thoroughly, on schedule and under budget.
Now we have been presented with a five year plan for sales growth in the US, NZ, Australia, Spain and Asia, and the diversification into four product streams for Cxbladder.
Again most investors seem to retain confidence in Pacific Edge because they have a history of meeting objectives. This is not ‘hype’, its credibility.
My DCF suggests Pacific Edge are fairly valued at present if only US Cxbladder(detect) revenue streams are considered.
The challenge for intso’s and analysts when PEB become NZ50 listed, will be similar to my own at present, in valuing the other forward revenue streams.
The greatest benefit of the NZ50 listing, as I see it, is that institutional analysts will gain better direct access to PEB than the rest of us have in assessing and valuing these streams.
Forward revenue streams to be assessed for a full 2014 valuation workup;
Cxbladder(detect) – US
Cxbladder(detect) – Spain
Cxbladder(detect) - Asia
Cxbladder(triage) – US, Spain, NZ, Australia, Asia
Cxbladder(predict) - US, Spain, NZ, Australia, Asia
Cxcolorectal – also likely to be launched in 2014
Pacific edge is undervalued at present, the difficulty is in accurately determining by how much without sufficient information on these other streams being available to most of us.
In addition, if PEB achieve ‘tens of thousands of tests’ in 2014 it may well bring forward discounted cashflows ahead of what analysts, including myself, are presently allowing for.
Bring forward cashflows would allow PEB to progress the pipeline products earlier, thus creating a compounding growth effect.
Snapiti - could you confirm whether you are a disappointed non-holder of PEB - or are just trying to ensure that those who do hold keep their feet on the ground about the relatively constant flow of good news announcements until they're backed with some real $$ of revenue.
Discl - hold over 300k at 71c average
So much for this closing in on the $2 mark... Couldn't of been more wrong with the price finishing lower today
No Wolf. Have been holding for quite some time now. Just find it interesting reading back a few pages to see what people say at one stage then come back and say in hindsight.
Patience is a virtue
Impatience is a sin
Why not stick you feet up
And have another gin
:)
"It remains that action will remove the doubts that theory cannot solve.
so only in pinning his friend's tail back on could Pooh have discovered that he would, in fact, be donkey-kicked in the face."
:mellow:
PEB has just been on T.V One news
Strange, a credibility announcement brings out more sellers than ever? weird how the market works...
It’s the strategic events or those that de-risk forward cashflows that matter.
The New Zealand market is small in the big picture, but I do like the formation of a HIH hot house type process for Cxbladder and potentially the pipeline products, that could be big deal not just for PEB but for other biotech companies coming to the fore.
The big events this year are likley to be the new product launches Cxbladder(predict), Cxbladder(triage) and possibly Cxcolorectal, none of which IMHO opinion are at all priced in. Also the new market entries into Spain and Asia on a similar basis. A final medicare sign up may de-risk for many also.
Yup exactly my thoughts, all these sellers could have sold at this price for some time but jst not the volume.
The latest announcement is actually very positive in terms of it's potential pathways into the market via GP'S. If PEB hadn't been looking to go into the USA and had been operating in NZ only this would be seen as a real green light announcement. The New Zealand branch of turnover will be a good sighter for growth potential in sales though so I'm looking forward to seeing how well received it is.